SonoBreast: Redefining Breast Ultrasound with AI

Breast cancer has become the leading threat to women’s health worldwide. In China, it ranks as the second most common malignancy among women, with incidence rising and affecting younger populations. Ultrasound has long been the preferred screening tool due to its safety and convenience, however, its diagnostic accuracy often varies, limited by the complexity of image interpretation, differences in physician experience, and the subtle presentation of malignant lesions.

To overcome these challenges, the field of ultrasound is rapidly evolving toward intelligent and standardized diagnostics—a key step toward improving accessibility and accuracy in breast cancer screening.

Pioneering Intelligent Diagnostics in Ultrasound

As a leader in ultrasound innovation, CHISON has been at the forefront of integrating AI with traditional ultrasound. From the early stages of AI development in the medical imaging field, CHISON has invested heavily in algorithm research and clinical validation, achieving breakthroughs in dynamic ultrasound image recognition and analysis.

Today, CHISON provides a full range of AI-assisted ultrasound solutions across cardiology, OB/GYN, vascular, thyroid, breast, and point-of-care applications. Among them, SonoBreast, CHISON’s intelligent breast diagnostic software, received medical device certification in 2022—marking a significant milestone in the practical application of AI-assisted ultrasound diagnosis in China.

Deep Learning Algorithms for Smart, Accurate Lesion Classification

Powered by advanced deep learning technology, SonoBreast is trained on a vast dataset of annotated breast ultrasound images. It can automatically detect and analyze features such as lesion morphology, boundary characteristics, and blood flow patterns—shifting diagnosis from “seeing the image” to “understanding the pathology.”

The system can identify even millimeter-level microlesions and calcifications, and evaluates them in accordance with BI-RADS standards. By providing a clear, quantitative, and visualized assessment interface, SonoBreast supports more consistent, objective, and reproducible diagnostic decisions—reducing variability caused by physician experience or fatigue.

Streamlining Workflow with Full Automation

Efficiency is another key advantage. SonoBreast automates what traditionally required over ten manual measurement steps, completing the analysis in just seconds. This not only enhances productivity but also helps clinicians focus more on patient care.

In regions where medical resources remain unevenly distributed, SonoBreast plays a vital role in empowering primary healthcare providers. Its standardized analysis tools assist less-experienced physicians in improving diagnostic accuracy and confidence—helping bridge the gap between different levels of medical institutions and making high-quality breast screening more accessible to women everywhere.

Looking ahead, CHISON remains dedicated to advancing the clinical integration of AI and expanding its applications across more diseases and complex clinical scenarios. As a global ultrasound technology leader, CHISON continues to bring intelligent imaging innovations to healthcare systems worldwide—helping clinicians deliver earlier, faster, and more accurate diagnoses.Through continuous innovation and international collaboration, we aim to make advanced ultrasound technology accessible to more people around the world, empowering a healthier future for all.